deltatrials
Completed PHASE1 INTERVENTIONAL 2-arm NCT02323607

Pacritinib and Chemotherapy in Treating Patients With Acute Myeloid Leukemia and FLT3 Mutations

Phase I Study of Pacritinib and Chemotherapy in Patients With Acute Myeloid Leukemia and FLT3 Mutations

Sponsor: Bhavana Bhatnagar

Conditions Recurrent Adult Acute Myeloid Leukemia Secondary Acute Myeloid Leukemia Therapy-Related Acute Myeloid Leukemia Untreated Adult Acute Myeloid Leukemia
Interventions Cytarabine Daunorubicin Hydrochloride Decitabine Laboratory Biomarker Analysis Pacritinib Pharmacological Study
Updated 10 times since 2017 Last updated: Jan 23, 2019 Started: Jan 12, 2016 Primary completion: Jul 12, 2018 Completion: Jul 12, 2018
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02323607, this PHASE1 trial focuses on Recurrent Adult Acute Myeloid Leukemia and Secondary Acute Myeloid Leukemia and remains completed. Sponsored by Bhavana Bhatnagar, it has been updated 10 times since 2016, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotRecruiting~Feb 2017 – ~Aug 2017 · 6 months · monthly snapshotRecruiting~Aug 2017 – ~Jan 2018 · 5 months · monthly snapshotSuspended~Jan 2018 – ~Jun 2018 · 5 months · monthly snapshotRecruiting~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshotRecruiting~Aug 2018 – ~Feb 2019 · 6 months · monthly snapshotSuspended~Feb 2019 – ~Jan 2021 · 23 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 22 months · monthly snapshotCompleted

Change History

10 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1

  4. Feb 2019 — Jan 2021 [monthly]

    Completed PHASE1

    Status: Suspended → Completed

  5. Aug 2018 — Feb 2019 [monthly]

    Suspended PHASE1

    Status: Recruiting → Suspended

▶ Show 5 earlier versions

  1. Jun 2018 — Aug 2018 [monthly]

    Recruiting PHASE1

  2. Jan 2018 — Jun 2018 [monthly]

    Recruiting PHASE1

    Status: Suspended → Recruiting

  3. Aug 2017 — Jan 2018 [monthly]

    Suspended PHASE1

    Status: Recruiting → Suspended

  4. Feb 2017 — Aug 2017 [monthly]

    Recruiting PHASE1

  5. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE1

    First recorded

Jan 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Bhavana Bhatnagar
  • CTI BioPharma
Data source: Ohio State University Comprehensive Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations